Surveillance of transmitted HIV-1 antiretroviral drug resistance in the context of decentralized HIV care in Senegal and the Ebola outbreak in Guinea.
Aristid Ekollo MbangeDjiba KabaAbou Abdallah Malick DiouaraHalimatou Diop-NdiayeNdeye Fatou Ngom-NgueyeAhmed DiengSeynabou LoKine Ndiaye ToureMamadou FallWilfred Fon MbachamMariama Sadjo DialloMohamed CisseSouleymane MboupCoumba Toure KanePublished in: BMC research notes (2018)
Genotyping was successful from 54/69 (78.2%) and 31/50 (62.0%) isolates. In Senegal, TDR prevalence was 0% (mean duration since HIV diagnosis 4.08 ± 3.53 years). In Guinea, two patients exhibited SDRMs M184V (NRTI), T215F (TAM) and, G190A (NNRTI), respectively. TDR prevalence at this second site, however, could not be ascertained because of low sample size. Phylogenetic inference confirmed CRF02_AG predominance in Senegal (62.96%) and Guinea (77.42%). TDR prevalence in Senegal remains extremely low suggesting improved control measures. Continuous surveillance in both settings is mandatory and, should be done closest to diagnosis/transmission time and with larger sample size.
Keyphrases
- hiv positive
- hiv infected
- human immunodeficiency virus
- antiretroviral therapy
- hiv aids
- risk factors
- end stage renal disease
- hepatitis c virus
- public health
- hiv testing
- men who have sex with men
- ejection fraction
- chronic kidney disease
- peritoneal dialysis
- south africa
- hiv infected patients
- genome wide
- patient reported outcomes
- gene expression
- genetic diversity
- single cell
- highly efficient
- dna methylation